Inflammatory bowel disease (IBD) is a chronic relapsing disorder involving a dysregulated
host–microbiota interaction. IBD patients have been shown to possess an increased risk for …

Human subjects and their enteric microbiota have evolved together to reach a state of
mutual tolerance. Mounting evidence from both animal models and human studies suggests …

The prokaryotic and eukaryotic cells of the colon exist in a highly complex, but harmonious
relationship. Disturbances in this remarkable symbiosis can result in the development of …

Probiotics, for the treatment of inflammatory bowel disease, are a group of specific
nonpathogenic bacteria that are functionally and genetically defined by their ability to reduce …

Most conventional forms of drug therapy suppress or modify the host immunoinflammatory
response and neglect the other contributor to disease pathogenesis—the environmental …

The intestinal flora has a conditioning effect on intestinal homeostasis, delivering regulatory
signals to the epithelium, the mucosal immune system and to the neuromuscular activity of …

Bacteria are key initiating factors in the development of chronic intestinal inflammation that
characterizes the idiopathic inflammatory bowel diseases (IBDs), ulcerative colitis (UC) and …

Intestinal bacteria play a key role in inflammatory bowel disease. Probiotics attempt to
modify disease by favourably altering bacterial composition, immune status, and …

The normal colonic microflora is intimately involved in the aetiology of inflammatory bowel
diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD). These conditions …

Inflammatory bowel disease (IBD) is a chronic relapsing disorder that is increasing in
prevalence in Western society and has been linked to the development of colorectal cancer …